Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia - Wikidata - awgldk - TriplyDB

Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia

Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia

http://www.wikidata.org/entity/Q33819687

about

Effects of hydroxyurea treatment for patients with hemoglobin SC disease.Adherence to hydroxyurea, health-related quality of life domains, and patients' perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults.Do difficulties in swallowing medication impede the use of hydroxyurea in children?Update on the use of hydroxyurea therapy in sickle cell disease Sickle cell disease: a neglected chronic disease of increasing global health importance Interventions for preventing silent cerebral infarcts in people with sickle cell disease.Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: A Phase III international randomized clinical trial.Hydroxyurea use in Children with Sickle Cell Disease: Do Severely Affected Patients Use It and Does It Impact Hospitalization Outcomes?Novel Use of Hydroxyurea in an African Region With Malaria: Protocol for a Randomized Controlled Clinical Trial.ENHANCE-(Electronic Hydroxyurea Adherence): A Protocol to Increase Hydroxyurea Adherence in Patients with Sickle Cell Disease.Clinical risks and healthcare utilization of haematopoietic cell transplantation for sickle cell disease in the U.S. using merged databases.Hydroxyurea (hydroxycarbamide) for sickle cell disease.Interventions for chronic kidney disease in people with sickle cell disease.Health-related quality of life and adherence to hydroxyurea in adolescents and young adults with sickle cell disease.Hydroxyurea use in prevention of stroke recurrence in children with sickle cell disease in a developing country: A cost effectiveness analysis.Improved hydroxyurea effect with the use of text messaging in children with sickle cell anemia.Barriers to hydroxyurea adherence and health-related quality of life in adolescents and young adults with sickle cell disease.Blood transfusion versus hydroxyurea in beta-thalassemia in Iran: a cost-effectiveness study.Sickle cell disease: a malady beyond a hemoglobin defect in cerebrovascular disease.HABIT, a Randomized Feasibility Trial to Increase Hydroxyurea Adherence, Suggests Improved Health-Related Quality of Life in Youths with Sickle Cell Disease.Association between Participants' Characteristics, Patient-Reported Outcomes, and Clinical Outcomes in Youth with Sickle Cell Disease

P2860

Q33427950-1357F3CA-9646-4FFC-9CD0-31CEEC274FF3 Q33876417-B33E9B37-F484-49EA-A7C7-062F5E03047D Q34285113-67BF8646-EF8C-4BAF-9EB7-E4917ED22807 Q34737460-31FEF7BD-F032-4D37-924D-BA20002057E5 Q34852524-F3CE6196-3C5C-4C20-80D7-785DECA96500 Q36370980-C028FAAB-D1D3-49A0-A83C-8217CE88918B Q36470602-B2A30576-6758-4270-B929-EC5204B39A60 Q36711806-FC400568-03E2-445D-AD01-445669AE53FE Q37075880-6FF24D57-CBF5-4477-9354-683EE1C18AAF Q37345065-45EC60BF-3B35-4BC8-BE7C-7AD83AD958F9 Q38619234-846740C0-650E-419F-A97D-82987AEEEC5E Q38692796-455D579E-7998-42D0-84B6-288A57D559D0 Q38696578-CAA5BE80-26DA-41DB-8335-527D98E7F099 Q38789568-EB0408F7-FD8E-4B00-8942-6A5F9B5684D8 Q38957972-A5C2FD1B-1375-4C49-AA09-8173770227E0 Q39143787-7DBB226C-249F-4CD8-81B6-20642D544132 Q46784552-7385C65D-C89D-4303-AB29-2CF14FFB7341 Q47211906-C9E0684B-3400-41E6-8A5E-1C1844A7B184 Q48174073-A4199A8C-CAC1-4BB3-8301-8D9C22FD0DC5 Q52639727-AB41D1E5-C64B-4D1E-8BBB-C543690F716A Q57175438-72CC2B72-AF10-448E-B98C-B760DCBBB7E7

P2860

Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia

http://www.wikidata.org/entity/Q33819687

description

2013 nî lūn-bûn

@nan

2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Hydroxyurea is associated with ...... ildren with sickle cell anemia

@ast

Hydroxyurea is associated with ...... ildren with sickle cell anemia

@en

type

label

Hydroxyurea is associated with ...... ildren with sickle cell anemia

@ast

Hydroxyurea is associated with ...... ildren with sickle cell anemia

@en

prefLabel

Hydroxyurea is associated with ...... ildren with sickle cell anemia

@ast

Hydroxyurea is associated with ...... ildren with sickle cell anemia

@en

P1433

Q33819687-988812D5-3D3E-423D-89D4-25F142055ADB

P1476

Q33819687-C57B8C7A-FBAE-468E-8FED-4294F27D3A5D

P2093

Q33819687-028A58FE-46D5-4596-B1E2-8DC644B5EF31

Q33819687-47B9E6DA-74BB-4EA6-B2D5-75EF5A335040

Q33819687-66849B7B-7317-4DBF-8FC3-D3C0AF707DC8

Q33819687-7B66FD0C-3372-4231-BB33-200B5661F664

Q33819687-B964E49E-4098-40AB-9BC1-FA29FC9D06D3

Q33819687-CA96DDCB-E867-41D0-B5F4-5FE1AB694C4F

Q33819687-D2812723-6AAB-462B-A576-4482E0DBAA71

Q33819687-EB88B519-2D15-43A9-B05E-525C121679A8

Q33819687-F01A8906-8809-47C6-BBA8-0939ABE02C80

Q33819687-F83953B2-3071-47E5-AD62-D58DEA0B98BF

P2860

Q33819687-1378A1CB-8291-4B4A-B5FC-BA32720498E9

Q33819687-264D66BA-688A-4BBA-B318-DFBC6302CD91

Q33819687-29ECFDB8-0298-426B-B101-3CECEA4A6426

Q33819687-2F4FA3E4-C356-4319-A319-EB1C62BFA8EA

Q33819687-47327FB3-82D9-4DFC-BA18-61EBFA6C9255

Q33819687-775BCC58-A0E4-4E6E-9CBC-661B89AEED63

Q33819687-7CB5618A-F770-4E29-BD39-D69AD742FAEC

Q33819687-8C2564AD-9A94-49C9-A238-E1762A319C06

Q33819687-995A1752-C997-48F8-994B-FB9E6BDB56CF

Q33819687-A0FAE713-D164-4AE5-9D7B-1904C6D1B5AA

P304

Q33819687-C1393CB5-D145-47C5-B3FF-79C928167CBB

P31

Q33819687-B6C5DB58-BD15-4F2E-A449-BCBB80EA198E

P356

Q33819687-D3262AAD-D7FC-4E33-A43E-7970B02E0B34

P407

Q33819687-CA1707B2-9E3F-4E8F-9536-A8974F389CD3

P433

Q33819687-8B9A32A7-94CF-4649-A3D7-B5C7C06891E7

P478

Q33819687-4B282383-F970-4DED-B8DF-5D1E9501A2FB

P577

Q33819687-AE688C40-05CA-4B08-8076-7CEB74E80C64

P5875

Q33819687-04865F8F-08C3-4AE3-99F3-B841F2BF4D65

P698

Q33819687-AFB87C55-5F35-44E5-9194-91740B42B07E

P921

Q33819687-6376412F-A154-477B-B9C9-BA44BF5C535E

P932

Q33819687-FA24747F-7A91-4CF0-B423-73985071B5E0

P356

P1433

P1476

Hydroxyurea is associated with ...... ildren with sickle cell anemia

@en

P2093

BABY HUG Investigators

http://www.w3.org/2001/XMLSchema#string

Billie Fish

http://www.w3.org/2001/XMLSchema#string

Bruce W Thompson

http://www.w3.org/2001/XMLSchema#string

James F Casella

http://www.w3.org/2001/XMLSchema#string

Scott D Grosse

http://www.w3.org/2001/XMLSchema#string

Scott T Miller

http://www.w3.org/2001/XMLSchema#string

Sheree L Boulet

http://www.w3.org/2001/XMLSchema#string

Suzette O Oyeku

http://www.w3.org/2001/XMLSchema#string

Winfred C Wang

http://www.w3.org/2001/XMLSchema#string

Zhaoyu Luo

http://www.w3.org/2001/XMLSchema#string

P2860

How should cost data in pragmatic randomised trials be analysed?

Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children.

Administrative data sets and health services research on hemoglobinopathies: a review of the literature.

How I use hydroxyurea to treat young patients with sickle cell anemia.

Costing and cost analysis in randomized controlled trials: caveat emptor.

Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).

Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children.

Impact of hydroxyurea on clinical events in the BABY HUG trial.

Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea.

P304

677-683

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1542/PEDS.2013-0333

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

132

http://www.w3.org/2001/XMLSchema#string

P577

2013-09-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262044446

http://www.w3.org/2001/XMLSchema#string

P698

23999955

http://www.w3.org/2001/XMLSchema#string

P921

sickle-cell disease

P932

4074648

http://www.w3.org/2001/XMLSchema#string